Swedish Orphan Biovitrum AB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Aspaveli, the pegcetacoplan-based therapy developed in partnership with Apellis Pharmaceuticals Inc., for the treatment of C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. The recommendation covers use in patients aged 12 years and older and marks the first time a therapy for these indications is on the verge of formal European approval. The decision now moves to the European Commission, which is expected to issue a final ruling in early 2026.

Why the CHMP endorsement reflects a shift in rare kidney disease regulation

The CHMP’s endorsement is a pivotal regulatory signal that these two rare kidney conditions, long underserved by targeted therapy, are finally gaining the institutional attention and evidence-based pathway they have lacked for decades. Unlike other renal approvals that have largely focused on more prevalent conditions like IgA nephropathy or diabetic nephropathy, this opinion marks a rare convergence of a mechanistically validated drug with rigorous clinical data in an orphan disease context.

European regulatory bodies have traditionally been slower to move on glomerulopathies with high heterogeneity and small patient populations. This endorsement suggests an evolution in how regulators assess the benefit-risk balance in rare, progressive kidney diseases. While not a guarantee of market authorization, the CHMP’s nod typically precedes final Commission approval, making this a critical inflection point for clinical practice and commercial entry.

 

How pegcetacoplan’s mechanism is changing the treatment narrative

Aspaveli is a systemic formulation of pegcetacoplan, a targeted inhibitor of C3 and C3b within the complement cascade. By acting upstream in the complement pathway, pegcetacoplan addresses the fundamental driver of disease in both C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis.

This upstream targeting differs meaningfully from earlier complement inhibitors such as eculizumab, which focus downstream at the C5 level. While those agents have been used off-label, they have not demonstrated consistent benefit in patients with complement-mediated glomerulonephritis, in part due to the incomplete blockade of disease-driving mechanisms. Pegcetacoplan’s specificity for C3-related dysregulation presents a more direct intervention in the pathological process.

What sets the VALIANT study apart in a historically data-poor field

The CHMP opinion is based on data from the VALIANT Phase 3 study, which is currently the largest trial conducted in these patient populations. The 124-participant, multicenter, placebo-controlled study enrolled both adolescents and adults, including individuals with native and transplanted kidneys, creating a representative dataset that reflects real-world disease complexity.

The primary endpoint was the change in the urine protein-to-creatinine ratio at week 26, a validated surrogate for disease activity and progression risk. Pegcetacoplan demonstrated statistically significant reductions in proteinuria, stabilization of kidney function, and histologic improvement in C3 deposition. These outcomes, published in The New England Journal of Medicine, provide a degree of evidence robustness that has historically been lacking in these indications.

The trial’s design, with a randomised controlled period followed by an open-label extension, allows for both placebo-controlled efficacy comparisons and longitudinal observation of treatment durability. These structural elements are likely to be viewed positively by health technology assessment agencies evaluating cost-effectiveness and real-world relevance.

What the proposed label could change in treatment sequencing

If the European Commission adopts the CHMP recommendation, Aspaveli would be the first medicine approved in the European Union for the treatment of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in patients aged 12 and older. This would offer clinicians a mechanistically targeted alternative to the current standard of care, which often involves immunosuppressants with limited efficacy and high toxicity profiles.

The proposed label includes use in patients with both native and post-transplant kidneys. This is critical, as recurrence of disease after transplant is alarmingly common, with reports suggesting up to 90 percent recurrence in some cohorts. For nephrologists, this regulatory clarity would support earlier intervention and could alter transplant strategies entirely, potentially allowing for better graft preservation through preemptive or early post-transplant use.

Clinicians treating adolescents also gain a new tool, as very few nephrology drugs are approved for paediatric use in this space. The 12-and-above label opens therapeutic access for a vulnerable group often caught in clinical limbo between paediatric and adult care protocols.

What barriers could slow European uptake despite regulatory momentum

Despite the momentum created by the CHMP recommendation, several challenges may delay or limit real-world impact. Pricing and reimbursement negotiations across individual EU member states remain a significant hurdle. For rare diseases, access often hinges on national-level assessments that can stretch for months or years post-approval, especially where incidence is low and clinical trial evidence is limited in scope.

Another issue is the twice-weekly subcutaneous administration schedule. While feasible from a pharmacological perspective, it imposes a significant burden on adolescent and young adult patients already navigating chronic disease management. The logistics of home-based administration and the potential need for training or nurse-led care services could impact adoption.

Manufacturing scale-up is another factor to monitor. Swedish Orphan Biovitrum AB holds commercial rights for systemic pegcetacoplan outside the United States and will be responsible for production and distribution across multiple countries. Ensuring consistent supply and managing local regulatory requirements for batch release, pharmacovigilance, and logistics will be essential to sustaining access post-approval.

Why Sobi and Apellis are consolidating their position in complement therapeutics

The CHMP opinion serves as a broader endorsement of the pegcetacoplan platform. The drug has already secured approval in multiple geographies for paroxysmal nocturnal haemoglobinuria and is being pursued in geographic atrophy and other complement-driven indications. Its dual validation in hematology and nephrology places Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. among the front-runners in the complement therapeutics space.

The collaboration model between the two companies also merits attention. Swedish Orphan Biovitrum AB holds exclusive ex-U.S. rights for systemic use, while Apellis Pharmaceuticals Inc. controls U.S. rights and global ophthalmology programs. This structure has allowed each company to focus operational resources and regulatory efforts on distinct geographies and indications, a strategy that may be increasingly adopted by other mid-cap biopharma companies looking to de-risk global launches.

What signals regulators and clinicians will watch as approval nears

Over the next quarter, attention will turn to the European Commission’s final decision and the subsequent rollout of national-level health technology assessments. Clinicians will be looking for early access programs or compassionate use opportunities to begin treating high-risk patients, particularly transplant recipients at risk of recurrence.

Regulators are likely to monitor safety data from the open-label extension phase of VALIANT, as well as any emerging real-world data once commercial use begins. These datasets could influence reimbursement decisions and support future label expansions or post-marketing requirements.

Additionally, other developers of complement inhibitors, including those targeting the alternative and lectin pathways, will be watching closely. An approval in this setting may lower the barrier for related agents to enter trials or receive expedited review under orphan drug frameworks.

The broader question is whether pegcetacoplan’s anticipated approval will trigger a new era of complement-based nephrology, much like what anti-VEGF agents did for ophthalmology in the early 2000s.

  Apellis Pharmaceuticals Inc., Aspaveli, C3G, CHMP, EMA, glomerulopathy, IC-MPGN, nephrology, pegcetacoplan, rare kidney diseases, Swedish Orphan Biovitrum AB, VALIANT study